Literature DB >> 4082903

The effect of an increased ratio of carbidopa to levodopa on the pharmacokinetics of levodopa.

S Kaakkola, P T Männistö, E Nissinen, A Vuorela, R Mäntylä.   

Abstract

A randomized, cross-over study was designed to compare the effects of an increased ratio (from 1:10 to 1:4) of carbidopa to levodopa on the fate of levodopa and carbidopa in 11 healthy subjects. Four combinations of carbidopa/levodopa (10 mg/100 mg, 25 mg/100 mg, 25 mg/250 mg, 62.5/250 mg) were used. Plasma levodopa, carbidopa, dopamine and dopac concentrations as well as urinary excretions of levodopa and dopac were determined by a sensitive high-performance liquid chromatography with electrochemical detection after a single carbidopa/levodopa tablet. As the ratio of carbidopa to levodopa increased, there was a significant increase in apparent t1/2 and AUC values of levodopa. At the same time the urinary excretion of levodopa increased and that of dopac decreased. The plasma ratios of levodopa/dopamine and levodopa/dopac and the urinary ratio of levodopa/dopac also increased. There were less subjective side-effects in the 1:4 groups than in the 1:10 groups. It is concluded that increasing the amount of carbidopa in relation to levodopa may be beneficial and further clinical studies are clearly indicated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082903     DOI: 10.1111/j.1600-0404.1985.tb00888.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  15 in total

1.  Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.

Authors:  Lissa S Brod; Jason L Aldred; John G Nutt
Journal:  Mov Disord       Date:  2012-04-16       Impact factor: 10.338

2.  The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

Authors:  D R Robertson; N D Wood; H Everest; K Monks; D G Waller; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1989-07       Impact factor: 4.335

Review 3.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Voluntary oral dosing for precise experimental compound delivery in adult rats.

Authors:  Kyle C Chesler; Cara T Motz; Katie L Bales; Rachael A Allen; Harrison K Vo; Machelle T Pardue
Journal:  Lab Anim       Date:  2021-08-14       Impact factor: 2.908

5.  The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats.

Authors:  P S Leppert; M Cortese; J A Fix
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

6.  Vocal training, levodopa, and environment effects on ultrasonic vocalizations in a rat neurotoxin model of Parkinson disease.

Authors:  Cynthia A Kelm-Nelson; Alexander F L Brauer; Michelle R Ciucci
Journal:  Behav Brain Res       Date:  2016-03-26       Impact factor: 3.332

Review 7.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

8.  Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.

Authors:  Helena Heikkinen; Anu Varhe; Tarmo Laine; Jaakko Puttonen; Marjo Kela; Seppo Kaakkola; Kari Reinikainen
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

9.  Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.

Authors:  Yushi Kashihara; Yui Terao; Kensaku Yoda; Takeshi Hirota; Toshio Kubota; Miyuki Kimura; Shunji Matsuki; Masaaki Hirakawa; Shin Irie; Ichiro Ieiri
Journal:  Eur J Clin Pharmacol       Date:  2018-10-31       Impact factor: 2.953

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.